Abstract 861P
Background
TPF (Docetaxel, Cisplatin, and 5-FU) is recommended as the preferred induction chemotherapy regimen for patients(pts) with locally advanced head and neck squamous cell carcinomas (LA-HNSCCs). PD-1 inhibitor monotherapy or combined with chemotherapy are recommended as standard treatment for advanced HNSCC and explored as neoadjuvant therapy in operable LA-HNSCC. This study aims to explore the efficacy and safety of anti-PD-1 Tislelizumab combined with modified APF as neoadjuvant treatment for LA-OSCC.
Methods
In this prospective single-arm phase II trial (NCT05862168), pts histologically confirmed OSCC staging III-IVB (AJCC 8th) were included and received 3 cycles induction therapy with tislelizumab combined modified APF (tislelizumab [day 1]: 200mg, nab-PTX [day 1/8]: 100 mg/m2, CDDP [day 1-3]: 20 mg/ m2, 5-FU [continuous infusion on days 1-5]: 600 mg/m2, every 3 weeks). Surgery was followed within 6 weeks and individual adjuvant therapy was performed according to neoadjuvant pathological response. The primary endpoint was pathological complete response (pCR) rate. The second endpoints consisted of safety, major pathological response (MPR) rate, R0 resection rate, non-surgery-delay rate, event-free survival, disease-free survival and overall survival.
Results
Between May. 2023, and May. 2024, 20 pts were enrolled, of whom 15 pts underwent surgical resection. The pCR rate was 73% (11/15) and 80% (12/15) pts achieved MPR. All pts received R0 resection. There were 1 pt suffered treatment-related surgical delay. No surgery-related or treatment-related death occurred. Treatment-related adverse events (TRAE) of any grade were reported in 11/20 (55%) pts, 3 (15%) had grade 3 and 4 TRAE and all come from chemotherapy-related white blood cell count decreased, neutropenia, thrombocytopenia, anaemia, diarrhea and hypokalemia.
Conclusions
Tislelizumab combined with modified APF is a promising neoadjuvant treatment for LA-OSCC with high pCR rate and manageable adverse events. However, long term follow-up is necessary to confirm the effects on survival-related endpoints.
Clinical trial identification
NCT05862168.
Editorial acknowledgement
Funding
BeiGene Co, Ltd. provided the study drug tislelizumab.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
858P - Preoperative neoadjuvant chemoimmunotherapy for locally advanced head and neck squamous cell carcinoma patients: A prospective, single-arm, phase II clinical study
Presenter: Ping Han
Session: Poster session 02
862P - Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for “borderline resectable” oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS)
Presenter: Praveen Kumar Marimuthu
Session: Poster session 02
863P - Safety and efficacy of four courses of pembrolizumab combined with carboplatin and albumin-binding paclitaxel versus two courses of neoadjuvant therapy in patients with resectable head and neck squamous cell carcinoma: An optimal efficacy study (prospective, two-arm, phase II)
Presenter: Jinsong Li
Session: Poster session 02
Resources:
Abstract
866P - Neoadjuvant and adjuvant AK104 in patients with recurrent, resectable squamous cell carcinoma of the head and neck: A phase II study
Presenter: Lei Liu
Session: Poster session 02
868P - Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Winston Wong
Session: Poster session 02
869P - Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Presenter: Jérome Fayette
Session: Poster session 02